Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
174 Leser
Artikel bewerten:
(1)

Sentec Receives FDA Clearance for LuMon Electrical Impedance Tomography (EIT) System -- First EIT System Indicated for Premature Infants and for Spontaneously Breathing Patients in the United States

The LuMon System is also CE-marked under EU MDR and registered with TGA in Australia.

LINCOLN, R.I., Sept. 4, 2025 /PRNewswire/ -- Sentec, a global leader in non-invasive patient monitoring, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its LuMon Electrical Impedance Tomography (EIT) system for premature infant, infant, adolescent, and adult patients-making it the first EIT technology in the United States available for premature infants and for spontaneously breathing patients.

The LuMon EIT System delivers functional lung imaging directly at the NICU bedside-without radiation-helping clinicians better tailor therapy to each patient's unique needs.

The LuMon EIT System delivers functional lung imaging directly at the bedside-without radiation-helping clinicians better tailor therapy to each patient's unique needs.

Clearance for Premature Infant Use Supports NICU Clinicians to Personalize Ventilatory Care

While the LuMon System can be used to monitor a variety of patients, whether ventilated or spontaneously breathing, the premature infants and other patients in the NICU may stand to benefit the most from EIT's insights at the bedside.

"Neonatal patients present enormous complexity, especially for ventilation; there's very little room for error, particularly in our smallest patients - and the consequences can follow these babies all their lives," said Dr. David Tingay, Clinical Neonatologist and Respiratory Physiotherapist at Royal Children's Hospital in Melbourne, Australia.

Dr. Tingay has done extensive research with the LuMon EIT system in infant patients continued, "Without EIT, there's been no way for us to continuously see what is happening inside the lungs at the bedside to understand the impact of our interventions better as we perform them."

The ability to safely visualize lung function at the bedside, continuously and in real time, has enormous potential for guiding neonatal care and, according to Dr. Tingay, "EIT provides immediate imaging of regional lung function at the bedside. That visualization helps us better understand each patient's respiratory condition and determine the strategies we need to employ for their specific needs."

With the first-ever FDA clearance for premature infants and soft, fabric belts small enough for even very low birthweight infants, the LuMon System is positioned to help clinicians deliver gentle and effective respiratory care for the uniquely fragile and complex patients in the NICU.

While the basis of electrical impedance tomography and its use for imaging regional lung function has been present in research for many years, the LuMon system is first EIT technology available for routine clinical bedside use with premature infants in the United States, and can impact patient care and clinical decision making today.

Learn more about Electrical Impedance Tomography from Sentec

About Electrical Impedance Tomography

Electrical impedance tomography works by sending gentle, alternating currents through the thorax via a comfortable, skin-friendly fabric belt and measuring the resulting voltages to produce dynamic images of regional impedance variations due to breathing. This enables clinicians to evaluate real-time responses to regional ventilation changes such as those resulting from positioning, ventilator settings, and pharmaceuticals, facilitating more precise and individualized care decisions.

About the LuMon System

Designed for critical care environments, including neonatal, pediatric, and adult intensive care units, the LuMon System enables bedside monitoring of regional impedance variations in the thorax to support assessment of a patient's respiratory status. This information assists in the real-time evaluation of air distribution and lung recruitment, supporting timely interventions that may help improve patient outcomes.

About Sentec

Sentec is a Swiss-American medical device company specializing in respiratory care. Since its founding in 1999, Sentec utilizes a deep-tech approach that is founded on advanced science and avant-garde technologies for respiratory patients across care areas. Sentec provides healthcare professionals worldwide with non-invasive, continuous monitoring and effective therapeutic solutions.

Sentec logo

Photo - https://mma.prnewswire.com/media/2761412/sentec_lumon_eit_system_in_nicu.jpg

Logo - https://mma.prnewswire.com/media/2761411/Sentec_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/sentec-receives-fda-clearance-for-lumon-electrical-impedance-tomography-eit-system--first-eit-system-indicated-for-premature-infants-and-for-spontaneously-breathing-patients-in-the-united-states-302545832.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.